title: "MIATA"-minimal information about T cell assays.
abstract: Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Janetzki
authors.forename: Cedrik M
authors.initials: CM
authors.lastname: Britten
authors.forename: Michael
authors.initials: M
authors.lastname: Kalos
authors.forename: Hyam I
authors.initials: HI
authors.lastname: Levitsky
authors.forename: Holden T
authors.initials: HT
authors.lastname: Maecker
authors.forename: Cornelius J M
authors.initials: CJ
authors.lastname: Melief
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Pedro
authors.initials: P
authors.lastname: Romero
authors.forename: Axel
authors.initials: A
authors.lastname: Hoos
authors.forename: Mark M
authors.initials: MM
authors.lastname: Davis
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007118:Immunoassay / Q000592:standards*; D007167:Immunotherapy; D015166:Monitoring, Immunologic / Q000592:standards*; D009369:Neoplasms / Q000628:therapy*; D017410:Practice Guidelines as Topic / Q000592:standards*; D013601:T-Lymphocytes / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*; D014777:Virus Diseases / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D014765:Viral Vaccines